# Teva Branded Pharmaceutical Products trials: 24 (2026)

ClinicalTrials.gov lists 24 trials with Teva Branded Pharmaceutical Products R&D LLC as lead sponsor, 6 of them recruiting or not yet recruiting.

## The full list

Clinical trials led by Teva Branded Pharmaceutical Products R&D LLC: 24 rows for $5, every trial on ClinicalTrials.gov. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/teva-branded-pharmaceutical-products-r-and-d-llc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 24
- Recruiting or not yet: 6
- Read on: November 19, 2026

## Trials

The 24 newest of 24, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 5, 2026 | NCT07920211 | Two Trials to Evaluate TEV-53408 in Participants With Non-Segmental Vitiligo | Teva Branded Pharmaceutical Products R&D LLC | Phase 2/3 | Not yet recruiting | Vitiligo | 1,020 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07920211) |
| November 3, 2026 | NCT07913100 | Real-World Impact of TV-44749 in Adults With Schizophrenia | Teva Branded Pharmaceutical Products R&D LLC | Observational | Not yet recruiting | Schizophrenia | 1,085 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07913100) |
| June 30, 2026 | NCT07674940 | A Trial to Assess TEV-56286 at Different Doses in Healthy Participants | Teva Branded Pharmaceutical Products R&D LLC | Phase 1 | Recruiting | Healthy Volunteers | 69 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07674940) |
| May 22, 2026 | NCT07601516 | Real World Effectiveness and Safety of Deutetrabenazine in Adult Chinese Participants With Huntington's Disease (HD) Chorea in China | Teva Branded Pharmaceutical Products R&D LLC | Phase 4 | Completed | Huntington's Disease, Chorea | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07601516) |
| September 29, 2025 | NCT07197866 | An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy | Teva Branded Pharmaceutical Products R&D LLC | Phase 2 | Recruiting | Multiple System Atrophy | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07197866) |
| April 4, 2025 | NCT06911567 | A Study to Assess New Formulations of TEV-56286 | Teva Branded Pharmaceutical Products R&D LLC | Phase 1 | Completed | Healthy Participants | 47 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06911567) |
| February 4, 2025 | NCT06807463 | A Trial to Assess the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease | Teva Branded Pharmaceutical Products R&D LLC | Phase 2 | Active not recruiting | Celiac Disease | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06807463) |
| October 29, 2024 | NCT06664619 | A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in... | Teva Branded Pharmaceutical Products R&D LLC | Phase 3 | Completed | Asthma | 649 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06664619) |
| October 3, 2024 | NCT06625177 | A Trial to Test the Safety and Efficacy of TEV-53408 in Participants With Vitiligo | Teva Branded Pharmaceutical Products R&D LLC | Phase 1 | Recruiting | Vitiligo | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06625177) |
| August 23, 2024 | NCT06568237 | A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy | Teva Branded Pharmaceutical Products R&D LLC | Phase 2 | Active not recruiting | Multiple System Atrophy | 349 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06568237) |
| June 28, 2024 | NCT06480552 | An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With... | Teva Branded Pharmaceutical Products R&D LLC | Phase 1 | Recruiting | Advanced Solid Tumors | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06480552) |
| March 19, 2024 | NCT06319170 | Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Participants With Schizophrenia/Schizoaffective... | Teva Branded Pharmaceutical Products R&D LLC | Phase 1 | Completed | Schizophrenia, Schizoaffective Disorder | 106 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06319170) |
| March 18, 2024 | NCT06315283 | An Open-Label Trial to Assess the Comparative Bioavailability of TV-44749 to Oral Olanzapine in Participants With Schizophrenia | Teva Branded Pharmaceutical Products R&D LLC | Phase 1 | Completed | Schizophrenia | 153 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06315283) |
| February 12, 2024 | NCT06253546 | Safety, Tolerability, and Pharmacokinetic Study of TV-44749 in Chinese Patients With Schizophrenia | Teva Branded Pharmaceutical Products R&D LLC | Phase 1 | Completed | Schizophrenia | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06253546) |
| September 25, 2023 | NCT06052267 | A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations | Teva Branded Pharmaceutical Products R&D LLC | Phase 3 | Active not recruiting | Asthma | 2,769 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06052267) |
| January 23, 2023 | NCT05693935 | A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label, Long-Term Safety Phase to Evaluate the Efficacy and Safety of... | Teva Branded Pharmaceutical Products R&D LLC | Phase 3 | Completed | Schizophrenia | 675 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05693935) |
| December 29, 2022 | NCT05668013 | A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease | Teva Branded Pharmaceutical Products R&D LLC | Phase 2 | Active not recruiting | Crohn Disease, Colitis, Ulcerative | 247 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05668013) |
| October 21, 2022 | NCT05590377 | A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma | Teva Branded Pharmaceutical Products R&D LLC | Phase 1/2 | Terminated | Multiple Myeloma | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05590377) |
| September 27, 2022 | NCT05556616 | A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma | Teva Branded Pharmaceutical Products R&D LLC | Phase 1 | Terminated | Multiple Myeloma | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05556616) |
| August 28, 2020 | NCT04530110 | A Trial to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents | Teva Branded Pharmaceutical Products R&D LLC | Phase 3 | Completed | Migraine | 499 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04530110) |
| May 19, 2020 | NCT04392648 | A Study to Evaluate the Safety, Tolerability and Efficacy of Intravenous TAK-573 as Part of Combination Therapy in Participants With... | Teva Branded Pharmaceutical Products R&D LLC | Phase 1 | Withdrawn | Relapsed and/or Refractory Multiple Myeloma | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04392648) |
| November 8, 2019 | NCT04157517 | A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors | Teva Branded Pharmaceutical Products R&D LLC | Phase 1/2 | Terminated | Neoplasms, Melanoma | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04157517) |
| May 29, 2018 | NCT03539393 | Fremanezumab Managed Access Program for Pediatric Patients | Teva Branded Pharmaceutical Products R&D LLC | Not applicable | Available | Migraine | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03539393) |
| July 12, 2017 | NCT03215030 | A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma | Teva Branded Pharmaceutical Products R&D LLC | Phase 1/2 | Terminated | Multiple Myeloma | 272 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03215030) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 9 |
| Phase 1/2 | 3 |
| Phase 2 | 4 |
| Phase 2/3 | 1 |
| Phase 3 | 4 |
| Phase 4 | 1 |
| Not applicable | 1 |
| Observational | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 8 |
| Recruiting | 4 |
| Terminated | 4 |
| Active not recruiting | 4 |
| Not yet recruiting | 2 |
| Available | 1 |
| Withdrawn | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Schizophrenia | 5 |
| Multiple Myeloma | 3 |
| Vitiligo | 2 |
| Migraine Disorders | 2 |
| Multiple System Atrophy | 2 |
| Asthma | 2 |
| Neoplasms | 1 |
| Melanoma | 1 |
| Huntington Disease | 1 |
| Chorea | 1 |
| Psychotic Disorders | 1 |
| Crohn Disease | 1 |
| Colitis, Ulcerative | 1 |
| Celiac Disease | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Bar and grill restaurants in the United States](https://specstream.ai/data/businesses/bar-and-grill-restaurants/united-states)
- [Neuropathology practices in the United States](https://specstream.ai/data/businesses/neuropathology-practices/united-states)
- [Business banking companies in the United States](https://specstream.ai/data/businesses/business-banking-companies/united-states)
- [Paving contractors in the United States](https://specstream.ai/data/businesses/paving-contractors/united-states)
- [Chinese restaurants in the United States](https://specstream.ai/data/businesses/chinese-restaurants/united-states)
